Avaliação de chumbo para desfibrilação e confiabilidade (LEADR)
The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead.
The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The LEADR and LEADR LBBAP studies will enroll subjects who are indicated to receive an implantable single or dual chamber ICD, or CRT-D, and who meet all of the inclusion criteria and none of the exclusion criteria. Subjects will receive an investigational Next Generation ICD Lead. Subjects in the LEADR study will be followed for at least 18 months following Next Generation ICD Lead implantation in a septal (non-LBBAP) or apical implant location. Enrollment in the LEADR study has been completed (675 subjects enrolled). Subjects in the LEADR LBBAP study will be followed for at least 3 months (ICD-indicated subjects) or 6 months (CRT-indicated subjects) following Next Generation ICD Lead implantation in an LBBAP implant location. Enrollment in the LEADR LBBAP study has been completed (332 subjects enrolled).
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Bielefeld
-
Bielefeld, Bielefeld, Alemanha, 33604
- LEADR: Klinikum Bielefeld Kardiologie
-
-
-
-
-
Garran, Austrália, 2605
- LEADR &LEADR LBBAP: Canberra Hospital
-
-
Queensland
-
Chermside, Queensland, Austrália, 4032
- LEADR & LEADR LBBAP: The Prince Charles Hospital
-
-
South Australia
-
Ashford, South Australia, Austrália, 8032
- LEADR: Ashford Hospital
-
Norwood, South Australia, Austrália, 5000
- LEADR & LEADR LBBAP: Royal Adelaide
-
-
-
-
Antwerp
-
Edegem, Antwerp, Bélgica, 2650
- LEADR LBBAP: Universitair Ziekenhuis Antwerpen
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 4N1
- LEADR: University of Calgary
-
-
Ontario
-
Newmarket, Ontario, Canadá, L3Y8C3
- LEADR: Southlake Regional Health Centre
-
-
Quebec
-
Québec, Quebec, Canadá, G1V 4G5
- LEADR & LEADR LBBAP: Institut Universitaire de Cardiologie et de Pneumologie de Quebec
-
-
-
-
-
Chengdu, China
- LEADR & LEADR LBBAP: West China Hospital of Sichuan University
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030000
- LEADR: Shanxi Cardiovascular Hospital
-
-
-
-
Singapore
-
Singapore, Singapore, Cingapura
- LEADR: Ng Teng Fong General Hospital
-
-
-
-
-
Copenhagen, Dinamarca, 2100
- LEADR: Rigshospitalet
-
-
-
-
-
L'Hospitalet de Llobregat, Espanha
- LEADR: Hospital Universitari Bellvitge
-
Valencia, Espanha, 46026
- LEADR: Hospital Universitario y Politécnico La Fe
-
-
Granada
-
Granada, Granada, Espanha, 18014
- LEADR LBBAP: Hospital Universitario Virgen de las Nieves
-
-
-
-
Alabama
-
Huntsville, Alabama, Estados Unidos, 35801
- LEADR: Heart Center Research
-
-
California
-
Torrance, California, Estados Unidos, 90505
- LEADR LBBAP: Torrance Memorial Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos, 06106
- LEADR: Hartford Hospital
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33606
- LEADR: University of South Florida
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55407
- LEADR & LEADR LBBAP: Minneapolis Heart Institute Foundation
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64111
- LEADR: Saint Luke's Mid America Heart Institute
-
St Louis, Missouri, Estados Unidos, 63110
- LEADR: Washington University School of Medicine
-
-
New Jersey
-
Voorhees Township, New Jersey, Estados Unidos, 08034
- LEADR: Lourdes Cardiology Services
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87108
- LEADR: Presbyterian Heart Group
-
-
New York
-
Bay Shore, New York, Estados Unidos, 11030
- LEADR & LEADR LBBAP: South Shore University Hospital/Northwell Health
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45202
- LEADR: TriHealth Hatton Research Institute
-
Cincinnati, Ohio, Estados Unidos, 45219
- LEADR LBBAP: The Christ Hospital
-
Cleveland, Ohio, Estados Unidos, 44195
- LEADR: Cleveland Clinic
-
Columbus, Ohio, Estados Unidos, 43210
- LEADR LBBAP: The Ohio State University Wexner Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18103
- LEADR: Lehigh Valley Hospital - Cedar Crest
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- LEADR: Hospital of the University of Pennsylvania
-
Wilkes-Barre, Pennsylvania, Estados Unidos, 18711
- LEADR LBBAP: Geisinger Wyoming Valley Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- LEADR& LEADR LBBAP: Vanderbilt University medical Center
-
-
Texas
-
Austin, Texas, Estados Unidos, 78705
- LEADR: Texas Cardiac Arrhythmia Research Foundation
-
Fort Worth, Texas, Estados Unidos, 76104
- LEADR: Texas Health Fort Worth Hospital
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22903
- LEADR & LEADR LBBAP: University of Virginia Medical Center
-
Richmond, Virginia, Estados Unidos, 23298
- LEADR & LEADR LBBAP: Virginia Commonwealth University Health System
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- LEADR LBBAP: Aurora St. Luke's Hospital
-
-
-
-
-
La Tronche, França, 38700
- LEADR: Centre Hospitalier Universitaire de Grenoble - Site Nord
-
Montpellier, França, 34960
- LEADR LBBAP: OC Santé - Clinique du Millénaire
-
Rouen, França, 76031
- LEADR: CHU Hôpitaux de Rouen - Hôpital Charles Nicolle
-
-
-
-
Limburg
-
Maastricht, Limburg, Holanda
- LEADR LBBAP: Maastricht Universitair Medisch Centrum
-
-
-
-
-
Hong Kong, Hong Kong
- LEADR & LEADR LBBAP: Queen Mary Hospital
-
Lai Chi Kok, Hong Kong, 999077
- LEADR: Princess Margaret Hospital
-
-
-
-
-
Bergamo, Itália, 24127
- LEADR: Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII
-
-
-
-
Fukuoka
-
Kitakyushu, Fukuoka, Japão, 802-8555
- LEADR & LEADR LBBAP: Kokura Memorial Hospital
-
-
Osaka
-
Suita, Osaka, Japão, 564-8565
- LEADR & LEADR LBBAP: National Cerebral and Cardiovascular Center
-
-
Tokyo
-
Shinjuku-Ku, Tokyo, Japão, 162-8666
- LEADR: Tokyo Women's Medical University Hospital
-
-
-
-
-
Kuala Lumpur, Malásia, 50400
- LEADR & LEADR LBBAP: Institut Jantung Negara - National Heart Institute
-
-
-
-
-
Krakow, Polônia
- LEADR LBBAP: Szpital Uniwersytecki w Krakowie
-
-
-
-
-
Carnaxide, Portugal, 2790-134
- LEADR: Centro Hospitalar de Lisboa Ocidental, E.P.E. Hospital de Santa Cruz Cardiology
-
-
-
-
-
London, Reino Unido, W12 0HS
- LEADR & LEADR LBBAP: Imperial College Healthcare NHS Trust - Hammersmith Hospital
-
-
-
-
-
Belgrade, Sérvia
- LEADR: Klinicki Centar Srbije Pejsmejker centar
-
-
-
-
Mitterweg
-
Krems, Mitterweg, Áustria, 3500
- LEADR: Universitätsklinikum Krems
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
LEADR Inclusion Criteria:
-
Subject meets current clinical practice guidelines for implantation of ICD or CRT-D and will undergo one of the following:
- de novo Medtronic CRT-D system implant
- de novo Medtronic ICD system implant (single or dual chamber)
-
Subject has, per local law and requirements, the minimum age for autonomously signing an ICF (minimum age of 18 years)
-
Subject is willing to undergo implant defibrillation testing if requested.
-
Subject is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up.
LEADR Exclusion Criteria:
-
Subject is unwilling or unable to personally provide Informed Consent.
-
Subject has contraindications for standard RV transvenous lead placement (e.g., mechanical right heart valve).
-
Subject is contraindicated for ≤1 mg dexamethasone acetate.
-
Subject has a life expectancy of less than 12 months
-
For subject undergoing defibrillation testing the following medical conditions exclude them:
- Pre-existing or suspected pneumothorax during implant
- Current intracardiac left atrial or left ventricular (LV) thrombus
- Severe aortic stenosis
- Severe proximal three-vessel or left main coronary artery disease without revascularization
- Unstable angina
- Ejection Fraction less than 25%
- Recent stroke or transient ischemic attack (within the last 6 months)
- Known inadequate external defibrillation
- Any other known medical condition not listed that precludes their participation in the opinion of the investigator
-
Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager.
-
Subject with any exclusion criteria as required by local law (e.g., age or other).
-
Pregnant women or breastfeeding women, or women of childbearing potential and who are not on a reliable form of birth regulation method or abstinence
-
Subject with an existing pacemaker (including transcatheter pacing system), ICD, or CRT device or leads
-
Subject with any evidence of active infection or undergoing treatment for an infection
-
Recent (or planned) cardiac surgery or stenting less than 1 month before implant
-
End stage renal disease
-
Subjects with NYHA IV classification
-
Subjects with a transplanted heart
-
Subjects with previously extracted leads
-
Subjects with Left Ventricular Assist Device
LEADR LBBAP Inclusion Criteria:
-
Subject meets current local clinical practice guidelines for implantation of ICD (single or dual chamber) or CRT-D system and will undergo one of the following:
a) De novo Medtronic ICD system implant (single or dual chamber) or b) De novo Medtronic CRT-D system implant and is intended to also undergo LV lead implant (for patients indicated for CRT-D according to locally approved indications/indications)
-
Subject is 12 years of age or older and also is greater than 30 kg in weight at time of enrollment, has cardiac anatomy conducive to RV coil placement, and is allowed to participate in study per local law and requirements. Subjects from 12 years of age until adult also have a separate indication for pacing or CRT or are anticipated to develop one.
-
Subject provides written authorization and/or consent per institution and geographical requirements.
-
Subject is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up
-
Subject is willing to undergo implant defibrillation testing if requested
LEADR LBBAP Exclusion Criteria:
-
Subject has contraindication for screw-in active fixation transvenous lead placement (e.g., mechanical right heart valve)
-
Subject is contraindicated for ≤1 mg dexamethasone acetate
-
Subject has a life expectancy of less than 12 months
-
For subject undergoing defibrillation testing the following medical conditions exclude them:
- Pre-existing or suspected pneumothorax
- Current intracardiac left atrial or LV thrombus
- Severe aortic stenosis
- Severe proximal three-vessel or left main coronary artery disease without revascularization
- Unstable angina
- Recent stroke or transient ischemic attack (within the last 6 months)
- Known inadequate external defibrillation
- Any other known medical condition not listed that precludes their participation in the opinion of the investigator
-
Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager
-
Subject is pregnant or breastfeeding, or subject is of childbearing potential and not on a reliable form of birth regulation method or abstinence
-
Subject with an existing pacemaker (including transvenous and transcatheter pacing system), ICD (transvenous) or CRT-D (transvenous) device or leads
-
Subject with previous subcutaneous ICD (S-ICD), extravascular ICD (EV ICD) or Implantable Cardiac Monitor explanted within 30 days before implant
-
Subject with any evidence of active bacterial infection or undergoing treatment for a bacterial infection within the last 30 days
-
Recent (or planned) cardiovascular intervention within 30 days before or after implant, such as cardiac surgery, cardiac ablation, Percutaneous Coronary Intervention (PCI), or temporary cardiac pacing for >12 hours
-
Subjects with end stage renal disease
-
Subjects with NYHA IV classification
-
Subjects with a transplanted heart or on the waiting list for a heart transplant
-
Subjects with previously extracted leads
-
Subjects with Left Ventricular Assist Device
-
Subjects that are vulnerable adults
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Intervention/Treatment (LEADR)
Patients will be implanted with a Next Generation ICD Lead and undergo required electrical testing |
Required electrical testing for pacing, sensing, impedance and defibrillation will be completed |
|
Experimental: Intervention/Treatment (LEADR LBBAP)
Patients will be implanted with a Next Generation ICD Lead in the LBBAP location and undergo required electrical testing |
Required electrical testing for pacing, sensing, impedance and defibrillation will be completed |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
LEADR: Estimate the Rate of Major Lead Complication-free Rate at 6 Months
Prazo: Implant to 6 Months
|
Subjects free of Next Generation ICD lead-related complication at 6 months post-implant. |
Implant to 6 Months
|
|
LEADR: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead
Prazo: Day 1
|
Defibrillation testing will be completed in a subset of subjects at implant. |
Day 1
|
|
LEADR LBBAP: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead
Prazo: Day 1
|
Defibrillation testing will be completed with the Next Generation ICD Lead in the LBBAP location in a subset of subjects at implant. |
Day 1
|
|
LEADR LBBAP: The Lead-related Major Complication Rate at 3-months
Prazo: Implant to 3 Months
|
Subjects free of Next Generation ICD lead-related complication at 3 months post-implant. |
Implant to 3 Months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
LEADR: Estimate the Fracture-free Rate of the Next Generation ICD Lead
Prazo: up to 18 months
|
Subjects will be assessed at certain time points for Next Generation ICD lead fracture related to the Next Generation ICD lead. |
up to 18 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: George Crossley, MD, Vanderbilt University (LEADR)
- Investigador principal: Pugazhendhi Vijayaraman, MD, Geisinger Medical Center (LEADR LBBAP)
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- MDT19004 / MDT22048
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .